Fingerprint of ubiquitin coupled enzyme UBC13 in health and disease

IF 4.5 2区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Bioorganic Chemistry Pub Date : 2025-04-28 DOI:10.1016/j.bioorg.2025.108524

Ru-Yi Chen , Yan-Jun Liu , Ran Wang, Jing Yu, Jin-Jin Shi, Guan-Jun Yang, Jiong Chen

引用次数: 0

Abstract

Ubiquitination is one of the most well-known post-translational modifications in eukaryotes. UBC13 is an E2 ubiquitin coupling enzyme, which interacts with different E3 ligases and exerts ubiquitination activity to assemble and synthesize lysine-63-linked (Lys63) ubiquitin strands, thus playing an important role in cell homeostasis, various diseases caused by inflammation, and the occurrence and development of cancer. In this paper, we review the structure and function of UBC13, summarize the diverse pathways it mediates, and discuss its involvement in bacterial and non-bacterial inflammatory diseases. Additionally, we explore UBC13's role in physiological damage repair mechanisms, cancer development, DNA damage repair, immune cell maturation, and function. Furthermore, We also elucidate the progress of the discovery of small molecule inhibitors targeting UBC13 and summarize their structure, which suggests that targeting UBC13 may be a potential disease treatment strategy.

Abstract Image

查看原文本刊更多论文

泛素偶联酶UBC13在健康和疾病中的指纹图谱

泛素化是真核生物中最著名的翻译后修饰之一。UBC13是E2泛素偶联酶，与不同的E3连接酶相互作用，发挥泛素化活性，组装合成lysine-63-linked （Lys63）泛素链，在细胞内稳态、各种炎症引起的疾病、癌症的发生发展中发挥重要作用。本文综述了UBC13的结构和功能，总结了其介导的多种途径，并讨论了其在细菌性和非细菌性炎症疾病中的作用。此外，我们还探讨了UBC13在生理损伤修复机制、癌症发展、DNA损伤修复、免疫细胞成熟和功能中的作用。此外，我们还阐述了靶向UBC13的小分子抑制剂的发现进展，并总结了它们的结构，这表明靶向UBC13可能是一种潜在的疾病治疗策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioorganic Chemistry 生物-生化与分子生物学

CiteScore

9.70

自引率

3.90%

发文量

679

审稿时长

31 days

期刊介绍： Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry. For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature. The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.